A Real World Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to Standard of Care Basal Insulin in Patients Already Using Basal Insulin
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 609 participants.
Also called NCT02967211
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 609 participants
- Sponsor
- Registry
-
NCT02967211 -
2015-001832-39
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Brazil, Finland, France, Greece, Ireland, Italy, Romania, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02967211. Randomized; no masking; primary purpose treatment. Start 2015-12-21 (registry gives no type); primary completion 2017-10-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin
- Acronym
- REGAIN CONTROL
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- insulin glargine (U300)
- Intervention (Drug)
- insulin glargine (U100)
- Intervention (Drug)
- NPH insulin
- Intervention (Drug)
- insulin detemir
- Intervention (Drug)
- insulin degludec
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02967211- Content hash
320f912e0ec21585215e2c1ea2cce1b3dd1d9a1b9216a50d962c90186e840ac8